1. Skip to navigation
  2. Skip to content
  3. Skip to sidebar

Treatment of Gastro-Intestinal Disorders

The GI system is one of the critical systems within the body and it has a major effect on quality of life. The gastrointestinal (GI) system has a major effect on an individual’s daily activities and quality of life. It is thought that every year at least 30% of people suffer from one or more episodes of common GI disorders severe enough to require medical attention.

In the US alone, GI diseases result in nearly 200 million sick days, 72 million visits to physicians, 14 million hospital discharges and nearly 240,000 deaths per year. More than 200 million people in the US and EU alone report some type of GI disorder. The total cost to third party payers and the government from GI diseases in the US is estimated between $60-$100 billion in indirect and direct health care expenditure (hospitalization, ambulatory cost, drugs, investigations, doctor visits).

The worldwide GI drug market is estimated to be worth at least $41 billion in annual sales, with more than 200 million people having some type of GI disorder in the US and Europe.

Altos Therapeutics is a specialty pharmaceutical company devoted to identifying and developing compounds for gastrointestinal disorders in areas of high un-meet medical need, possibly including functional dyspepsia, refractory gastro-esophageal reflux disease, gastroparesis and refractory nausea.

Have questions?

Contact us with questions or comments.

Contact us now